
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="D0BD41E4AC192A45000043835B346E2D.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="nnn" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC8488759/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488759/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Neurology&#x000ae; Neuroimmunology &#x00026; Neuroinflammation" /><meta name="citation_title" content="Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry" /><meta name="citation_author" content="Franziska S. Thaler" /><meta name="citation_author" content="Luise Zimmermann" /><meta name="citation_author" content="Stefan Kammermeier" /><meta name="citation_author" content="Christine Strippel" /><meta name="citation_author" content="Marius Ringelstein" /><meta name="citation_author" content="Andrea Kraft" /><meta name="citation_author" content="Kurt-Wolfram S&#x000fc;hs" /><meta name="citation_author" content="Jonathan Wickel" /><meta name="citation_author" content="Christian Geis" /><meta name="citation_author" content="Robert Markewitz" /><meta name="citation_author" content="Christian Urbanek" /><meta name="citation_author" content="Claudia Sommer" /><meta name="citation_author" content="Kathrin Doppler" /><meta name="citation_author" content="Loana Penner" /><meta name="citation_author" content="Jan Lewerenz" /><meta name="citation_author" content="Rosa R&#x000f6;&#x000df;ling" /><meta name="citation_author" content="Carsten Finke" /><meta name="citation_author" content="Harald Pr&#x000fc;ss" /><meta name="citation_author" content="Nico Melzer" /><meta name="citation_author" content="Klaus-Peter Wandinger" /><meta name="citation_author" content="Frank Leypoldt" /><meta name="citation_author" content="Tania K&#x000fc;mpfel" /><meta name="citation_author" content="on behalf of the German Network for Research on Autoimmune Encephalitis (GENERATE)" /><meta name="citation_publication_date" content="2021/11" /><meta name="citation_issue" content="6" /><meta name="citation_volume" content="8" /><meta name="citation_doi" content="10.1212/NXI.0000000000001088" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC8488759/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC8488759/" /><meta name="citation_pmid" content="34599001" /><meta name="DC.Title" content="Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="American Academy of Neurology" /><meta name="DC.Contributor" content="Franziska S. Thaler" /><meta name="DC.Contributor" content="Luise Zimmermann" /><meta name="DC.Contributor" content="Stefan Kammermeier" /><meta name="DC.Contributor" content="Christine Strippel" /><meta name="DC.Contributor" content="Marius Ringelstein" /><meta name="DC.Contributor" content="Andrea Kraft" /><meta name="DC.Contributor" content="Kurt-Wolfram S&#x000fc;hs" /><meta name="DC.Contributor" content="Jonathan Wickel" /><meta name="DC.Contributor" content="Christian Geis" /><meta name="DC.Contributor" content="Robert Markewitz" /><meta name="DC.Contributor" content="Christian Urbanek" /><meta name="DC.Contributor" content="Claudia Sommer" /><meta name="DC.Contributor" content="Kathrin Doppler" /><meta name="DC.Contributor" content="Loana Penner" /><meta name="DC.Contributor" content="Jan Lewerenz" /><meta name="DC.Contributor" content="Rosa R&#x000f6;&#x000df;ling" /><meta name="DC.Contributor" content="Carsten Finke" /><meta name="DC.Contributor" content="Harald Pr&#x000fc;ss" /><meta name="DC.Contributor" content="Nico Melzer" /><meta name="DC.Contributor" content="Klaus-Peter Wandinger" /><meta name="DC.Contributor" content="Frank Leypoldt" /><meta name="DC.Contributor" content="Tania K&#x000fc;mpfel" /><meta name="DC.Contributor" content="on behalf of the German Network for Research on Autoimmune Encephalitis (GENERATE)" /><meta name="DC.Date" content="2021 Nov" /><meta name="DC.Identifier" content="10.1212/NXI.0000000000001088" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry" /><meta property="og:type" content="article" /><meta property="og:description" content="To determine the real-world use of rituximab in autoimmune encephalitis (AE) and to correlate rituximab treatment with the long-term outcome.Patients with NMDA receptor (NMDAR)-AE, leucine-rich glioma-inactivated-1 (LGI1)- AE, contactin-associated protein-like-2 ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488759/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8488759/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2573/">Neurol Neuroimmunol Neuroinflamm</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/387389/">v.8(6); 2021 Nov</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC8488759
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC8488759/pdf/NEURIMMINFL2021038761.pdf" class="int-view">PDF (917K)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/8488759/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/8488759/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="8488759" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8488759%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="FG7nwHrnuFnq6XA6fN2jrscw4I00S2jOjoYvrLYEOh97P1UFz2An5rMtDJP7W2fP">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8488759%2F&amp;text=Rituximab%20Treatment%20and%20Long-term%20Outcome%20of%20Patients%20With%20Autoimmune%20Encephalitis%3A%20Real-world%20Evidence%20From%20the%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8488759%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488759/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC8488759/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/34599001/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC8488759/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/34599001/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC8488759/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/8488759/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2573/">Neurol Neuroimmunol Neuroinflamm</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/387389/">v.8(6); 2021 Nov</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC8488759
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-nnn.png" alt="Logo of nnn" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://nn.neurology.org/" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Neurol Neuroimmunol Neuroinflamm.</span> 2021 Nov; 8(6): e1088. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2021 Oct 1. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1212%2FNXI.0000000000001088" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1212/NXI.0000000000001088</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC8488759</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34599001">34599001</a></div></div></div><h1 class="content-title">Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis</h1><div class="fm-subtitle">Real-world Evidence From the GENERATE Registry</div><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Thaler%20FS%5BAuthor%5D">Franziska S. Thaler</a>, MD,<sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zimmermann%20L%5BAuthor%5D">Luise Zimmermann</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kammermeier%20S%5BAuthor%5D">Stefan Kammermeier</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Strippel%20C%5BAuthor%5D">Christine Strippel</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ringelstein%20M%5BAuthor%5D">Marius Ringelstein</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kraft%20A%5BAuthor%5D">Andrea Kraft</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=S&#x000fc;hs%20KW%5BAuthor%5D">Kurt-Wolfram S&#x000fc;hs</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wickel%20J%5BAuthor%5D">Jonathan Wickel</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Geis%20C%5BAuthor%5D">Christian Geis</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Markewitz%20R%5BAuthor%5D">Robert Markewitz</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Urbanek%20C%5BAuthor%5D">Christian Urbanek</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sommer%20C%5BAuthor%5D">Claudia Sommer</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Doppler%20K%5BAuthor%5D">Kathrin Doppler</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Penner%20L%5BAuthor%5D">Loana Penner</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lewerenz%20J%5BAuthor%5D">Jan Lewerenz</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=R&#x000f6;&#x000df;ling%20R%5BAuthor%5D">Rosa R&#x000f6;&#x000df;ling</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Finke%20C%5BAuthor%5D">Carsten Finke</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Pr&#x000fc;ss%20H%5BAuthor%5D">Harald Pr&#x000fc;ss</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Melzer%20N%5BAuthor%5D">Nico Melzer</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wandinger%20KP%5BAuthor%5D">Klaus-Peter Wandinger</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Leypoldt%20F%5BAuthor%5D">Frank Leypoldt</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=K&#x000fc;mpfel%20T%5BAuthor%5D">Tania K&#x000fc;mpfel</a>, MD, and  on behalf of the German Network for Research on Autoimmune Encephalitis (GENERATE)</div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139757126186416_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139757126186416_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139757126186416_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139757126186416_ai" style="display:none"><div class="fm-affl" id="aff-a.u.b.g.x">From the Institute of Clinical Neuroimmunology (F.S.T., T.K.), University Hospital and Biomedical Center, Ludwig-Maximilians-Universit&#x000e4;t, Munich; Section of Translational Neuroimmunology (L.Z., J.W., C.G.), Department of Neurology, Jena University Hospital, Jena; Department of Neurology (S.K.), University Hospital, Ludwig-Maximilians-University, Munich; Department of Neurology with Institute of Translational Neurology (Christine Strippel, N.M.), University of Muenster; Department of Neurology (M.R., N.M.), Medical Faculty, Heinrich Heine University D&#x000fc;sseldorf; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University D&#x000fc;sseldorf; Department of Neurology Martha-Maria Hospital (A.K.), Halle/Saale, Academic Hospital of University Halle-Wittenberg; Department of Neurology (K.-W.S.), Hannover Medical School; Department of Neurology (R.M., K.-P.W.), University Hospital Schleswig-Holstein, L&#x000fc;beck; Department of Neurology (C.U.), Klinikum der Stadt Ludwigshafen a. Rh. gGmbH, Ludwigshafen; Department of Neurology (C. Sommer, K.D.), University Hospital W&#x000fc;rzburg; Department of Neurology (L.P., J.L.), Ulm University; Department of Neurology and Experimental Neurology (R.R., C.F., H.P.), Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin; German Center for Neurodegenerative Diseases (DZNE) Berlin (R.R., H.P.); Neuroimmunology Section (K.-P.W., F.L.), Institute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel, L&#x000fc;beck; and,  Department of Neurology (F.L.), Christian-Albrechts-Universit&#x000e4;t Kiel, Germany.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div><span class="contrib-email" id="contrib-a.u.b.g.b">Luise Zimmermann: <a href="mailto:dev@null" data-email="moc.liamelgoog@ekpeor.esiul" class="oemail">moc.liamelgoog@ekpeor.esiul</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.c">Stefan Kammermeier: <a href="mailto:dev@null" data-email="ed.nehcneum-inu.dem@reiemremmak.nafets" class="oemail">ed.nehcneum-inu.dem@reiemremmak.nafets</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.d">Christine Strippel: <a href="mailto:dev@null" data-email="ed.retsneumku@leppirts.enitsirhc" class="oemail">ed.retsneumku@leppirts.enitsirhc</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.e">Marius Ringelstein: <a href="mailto:dev@null" data-email="ed.frodlesseud-inu.dem@nietslegnir.suiram" class="oemail">ed.frodlesseud-inu.dem@nietslegnir.suiram</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.f">Andrea Kraft: <a href="mailto:dev@null" data-email="ed.airam-ahtram@tfark.aerdna" class="oemail">ed.airam-ahtram@tfark.aerdna</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.g">Kurt-Wolfram S&#x000fc;hs: <a href="mailto:dev@null" data-email="ed.revonnah-hm@marflow-truk.sheus" class="oemail">ed.revonnah-hm@marflow-truk.sheus</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.h">Jonathan Wickel: <a href="mailto:dev@null" data-email="ed.anej-inu.dem@lekciw.nahtanoj" class="oemail">ed.anej-inu.dem@lekciw.nahtanoj</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.i">Christian Geis: <a href="mailto:dev@null" data-email="ed.anej-inu.dem@sieg.naitsirhc" class="oemail">ed.anej-inu.dem@sieg.naitsirhc</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.j">Robert Markewitz: <a href="mailto:dev@null" data-email="ed.hsku@ztiwekram.trebor" class="oemail">ed.hsku@ztiwekram.trebor</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.k">Christian Urbanek: <a href="mailto:dev@null" data-email="ed.ulilk@ckenabru" class="oemail">ed.ulilk@ckenabru</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.l">Claudia Sommer: <a href="mailto:dev@null" data-email="ed.grubzreuw-inu@remmos" class="oemail">ed.grubzreuw-inu@remmos</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.m">Kathrin Doppler: <a href="mailto:dev@null" data-email="ed.wku@k_relppod" class="oemail">ed.wku@k_relppod</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.n">Loana Penner: <a href="mailto:dev@null" data-email="ed.mlu-inu@rennep.anaol" class="oemail">ed.mlu-inu@rennep.anaol</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.o">Jan Lewerenz: <a href="mailto:dev@null" data-email="ed.mlu-inu@znerewel.naj" class="oemail">ed.mlu-inu@znerewel.naj</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.p">Rosa R&#x000f6;&#x000df;ling: <a href="mailto:dev@null" data-email="ed.etirahc@gnilsseor.asor" class="oemail">ed.etirahc@gnilsseor.asor</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.q">Carsten Finke: <a href="mailto:dev@null" data-email="ed.etirahc@eknif.netsrac" class="oemail">ed.etirahc@eknif.netsrac</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.r">Harald Pr&#x000fc;ss: <a href="mailto:dev@null" data-email="ed.etirahc@sseurp.dlarah" class="oemail">ed.etirahc@sseurp.dlarah</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.s">Nico Melzer: <a href="mailto:dev@null" data-email="ed.retsneumku@rezlem.ocin" class="oemail">ed.retsneumku@rezlem.ocin</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.t">Klaus-Peter Wandinger: <a href="mailto:dev@null" data-email="ed.hsku@regnidnaw.retep-sualk" class="oemail">ed.hsku@regnidnaw.retep-sualk</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.u">Frank Leypoldt: <a href="mailto:dev@null" data-email="ed.hsku@tdlopyel.knarf" class="oemail">ed.hsku@tdlopyel.knarf</a>; </span> <span class="contrib-email" id="contrib-a.u.b.g.v">Tania K&#x000fc;mpfel: <a href="mailto:dev@null" data-email="ed.nehcneum-inu.dem@lefpmeuk.ainat" class="oemail">ed.nehcneum-inu.dem@lefpmeuk.ainat</a></span> </div><div id="corresp-a.u.b.h.a"><strong>Correspondence</strong> Dr. Thaler <a href="mailto:dev@null" data-email="ed.nehcneum-inu.dem@relaht.aksiznarf" class="oemail">ed.nehcneum-inu.dem@relaht.aksiznarf</a></div><div id="fn-a.u.b.h.b">Go to <a href="https://nn.neurology.org/content/8/6/e088/tab-article-info" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">Neurology.org/NN</a> for full disclosures. Funding information is provided at the end of the article.</div><div id="fn-a.u.b.h.c">F. Leypoldt and T. K&#x000fc;mpfel contributed equally to this work as co&#x02013;senior authors.</div><div id="fn-a.u.b.h.d">German Network for Research on Autoimmune Encephalitis (GENERATE) coinvestigators are listed in <a href="#A2" rid="A2" class=" app">Appendix 2</a> at the end of the article.</div><div id="fn-a.u.b.h.e">The Article Processing Charge was funded by the authors.</div></div><div class="fm-article-notes hide half_rhythm" id="idm139757126186416_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2021 Feb 12; Accepted 2021 Aug 23.</div></div><div class="permissions half_rhythm hide" id="idm139757126186416_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</div><div class="license half_rhythm">This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</a>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-length="207" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p class="p p-first-last">No deidentified patient data will be shared. No study-related documents will be shared. Reasonable requests from any qualified investigator for anonymized data will be considered by the corresponding author.</p></dd></dl></div><div id="abstract-a.u.b.q" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.u.b.qtitle">Abstract</h2><!--article-meta--><div><div id="sec-a.u.b.q.a" class="sec sec-first"><h3 id="sec-a.u.b.q.atitle">Background and Objectives</h3><p class="p p-first-last">To determine the real-world use of rituximab in autoimmune encephalitis (AE) and to correlate rituximab treatment with the long-term outcome.</p></div><div id="sec-a.u.b.q.b" class="sec"><h3 id="sec-a.u.b.q.btitle">Methods</h3><p class="p p-first-last">Patients with NMDA receptor (NMDAR)-AE, leucine-rich glioma-inactivated-1 (LGI1)- AE, contactin-associated protein-like-2 (CASPR2)-AE, or glutamic acid decarboxylase 65 (GAD65) disease from the GErman Network for Research on AuToimmune Encephalitis who had received at least 1 rituximab dose and a control cohort of non&#x02013;rituximab-treated patients were analyzed retrospectively.</p></div><div id="sec-a.u.b.q.c" class="sec"><h3 id="sec-a.u.b.q.ctitle">Results</h3><p class="p p-first-last">Of the 358 patients, 163 (46%) received rituximab (NMDAR-AE: 57%, CASPR2-AE: 44%, LGI1-AE: 43%, and GAD65 disease: 37%). Rituximab treatment was initiated significantly earlier in NMDAR- and LGI1-AE (median: 54 and 155 days from disease onset) compared with CASPR2-AE or GAD65 disease (median: 632 and 1,209 days). Modified Rankin Scale (mRS) scores improved significantly in patients with NMDAR-AE, both with and without rituximab treatment. Although being more severely affected at baseline, rituximab-treated patients with NMDAR-AE more frequently reached independent living (mRS score &#x02264;2) (94% vs 88%). In LGI1-AE, rituximab-treated and nontreated patients improved, whereas in CASPR2-AE, only rituximab-treated patients improved significantly. No improvement was observed in patients with GAD65 disease. A significant reduction of the relapse rate was observed in rituximab-treated patients (5% vs 13%). Detection of NMDAR antibodies was significantly associated with mRS score improvement. A favorable outcome was also observed with early treatment initiation.</p></div><div id="sec-a.u.b.q.d" class="sec"><h3 id="sec-a.u.b.q.dtitle">Discussion</h3><p class="p p-first-last">We provide real-world data on immunosuppressive treatments with a focus on rituximab treatment for patients with AE in Germany. We suggest that early and short-term rituximab therapy might be an effective and safe treatment option in most patients with NMDAR-, LGI1-, and CASPR2-AE.</p></div><div id="sec-a.u.b.q.e" class="sec sec-last"><h3 id="sec-a.u.b.q.etitle">Class of Evidence</h3><p class="p p-first-last">This study provides Class IV evidence that rituximab is an effective treatment for some types of AE.</p></div></div></div><div id="body-a.v" class="tsec sec"><h2 class="headless nomenu"></h2><p class="p p-first">Autoimmune encephalitis (AE) is an umbrella term for an emerging spectrum of immune-mediated neuropsychiatric disorders often associated with antibodies (abs) against neuronal cell surface, synaptic, or intracellular proteins.<sup><a href="#R1" rid="R1" class=" bibr popnode">1</a>,<a href="#R2" rid="R2" class=" bibr popnode">2</a></sup> Anti-NMDA receptor (NMDAR)-AE, anti&#x02013;leucine-rich glioma-inactivated-1 (LGI1)-AE, anti&#x02013;contactin-associated protein-like-2 (CASPR2)-AE, and anti&#x02013;glutamic acid decarboxylase-65 (GAD65) disease together make up the majority of seropositive AE subtypes. NMDAR-AE affects young adults and children with female preponderance, is frequently associated with ovarian teratomas, and causes psychiatric symptoms, movement disorders, decreased consciousness, autonomic dysregulation, epileptic seizures, and central apnea.<sup><a href="#R3" rid="R3" class=" bibr popnode">3</a>,<a href="#R4" rid="R4" class=" bibr popnode">4</a></sup> LGI1-AE affects middle-aged or elderly patients, causes short-term memory deficits, confusion, and epileptic seizures,<sup><a href="#R5" rid="R5" class=" bibr popnode">5</a>,<a href="#R6" rid="R6" class=" bibr popnode">6</a></sup> and is sometimes preceded by faciobrachial dystonic or tonic seizures.<sup><a href="#R7" rid="R7" class=" bibr popnode">7</a></sup> CASPR2-AE predominantly affects elderly men and causes encephalitis and neuromyotonia, neuropathic pain, ataxia, myoclonus, autonomic dysfunction, or a combination thereof (e.g., Morvan syndrome).<sup><a href="#R8" rid="R8" class=" bibr popnode">8</a>,<a href="#R9" rid="R9" class=" bibr popnode">9</a></sup> GAD65 disease is considerably more heterogeneous, affects predominantly women of all ages, and may cause cerebellar ataxia (CA), limbic/AE (LE), stiff-person syndrome (SPS), isolated temporal lobe epilepsy, and overlap forms of the aforementioned manifestations.<sup><a href="#R10" rid="R10" class=" bibr popnode">10</a><a href="#R11" rid="R11" class=" bibr popnode">-</a><a href="#R13" rid="R13" class=" bibr popnode">13</a></sup></p><p class="p">Early diagnosis and prompt initiation of immunotherapy is crucial and often leads to substantial or complete recovery from these severe disorders.<sup><a href="#R8" rid="R8" class=" bibr popnode">8</a></sup> However, treatment data from randomized trials are scarce.<sup><a href="#R14" rid="R14" class=" bibr popnode">14</a>,<a href="#R15" rid="R15" class=" bibr popnode">15</a></sup> Empiric treatment of AE usually consists of a step-wise escalation of immunotherapy including first-line therapy with steroids, plasma exchange, IV immunoglobulin (IVIG), or combinations, followed by second-line therapy with cyclophosphamide, rituximab, or combinations.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a></sup> Rituximab is a B cell&#x02013;depleting monoclonal ab directed against CD20 with established efficacy in many neurologic autoimmune diseases including MS,<sup><a href="#R16" rid="R16" class=" bibr popnode">16</a></sup> and neuromyelitis optica spectrum disorders.<sup><a href="#R17" rid="R17" class=" bibr popnode">17</a></sup> Rituximab was shown to be effective in AE associated with different auto-abs.<sup><a href="#R4" rid="R4" class=" bibr popnode">4</a>,<a href="#R18" rid="R18" class=" bibr popnode">18</a>,<a href="#R19" rid="R19" class=" bibr popnode">19</a></sup> By contrast, 1 randomized placebo-controlled trial with rituximab did not show efficacy in patients with SPS.<sup><a href="#R15" rid="R15" class=" bibr popnode">15</a></sup> Detailed and comparative evaluations of rituximab use and the long-term outcome between AE subtypes in a real-world setting are missing. In this study, we evaluated demographic and clinical characteristics, laboratory findings, and immunotherapies in patients with NMDAR-, LGI1-, CASPR2-AE, or GAD65 disease in a cohort from the GErman NEtwork for Research on AuToimmune Encephalitis (GENERATE) registry and compared patients who had received at least 1 rituximab dose with non&#x02013;rituximab-treated patients. In the rituximab cohort, we specifically correlated early, high-dose, or prolonged rituximab treatment with the long-term outcome.</p></div><div id="s1" class="tsec sec"><h2 class="head no_bottom_margin" id="s1title">Methods</h2><div id="s1-1" class="sec sec-first"><h3 id="s1-1title">Standard Protocol Approvals, Registrations, and Patient Consents</h3><p class="p p-first">All data were collected from the GENERATE registry, which is a noninterventional retrospective and prospective multicentric database for patients with AE in Germany, Austria, and Switzerland (<a href="https://generate-net.de" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">generate-net.de</a>). GENERATE was approved by the institutional review boards of all actively recruiting centers. Patients from participating centers entered into the registry until June 30, 2019, were analyzed. The study was performed according to the Declaration of Helsinki. All enrolled patients or their legal representatives gave written informed consent before enrollment in the registry.</p><div id="s1-1-1" class="sec"><p></p><h4 id="s1-1-1title" class="inline">Study Population </h4><p class="p p-first-last">The following patients were included: (1) patients with detection of NMDAR-, LGI1-, CASPR2-, or GAD65 abs according to the ab criteria below; (2) clinical diagnosis of AE based on the consensus criteria published in reference 2, or for patients with GAD abs, alternatively diagnosis of CA or SPS; (3) any documented treatment with rituximab; and (4) available information on the number, dosage, and timing of rituximab infusions. In addition, a control cohort with consistent inclusion criteria except for rituximab treatment was included.</p></div><div id="s1-1-2" class="sec"><p></p><h4 id="s1-1-2title" class="inline">Analysis of Clinical, Laboratory, and Immunotherapy Profiles </h4><p class="p p-first">Ab testing was performed in the respective GENERATE centers using cell-based assays (CBAs) and confirmation by immunofluorescence (commercial test kit panels Euroimmun, L&#x000fc;beck) and/or immunohistochemistry (IHC) for NMDAR, LGI1, and CASPR2, and ELISA, radioimmunoassay (RIA), or CBA for GAD65. Patients fulfilling the following ab criteria in earliest available samples were included: NMDAR abs detected in serum by CBA confirmed by IHC (in the absence of confirmatory IHC in serum, only CBA serum titers of &#x0003e;1:500 were considered specific) and/or CSF positive; GAD abs &#x0003e;1:500 in CBA or &#x0003e;2000IE/mL in ELISA or RIA in serum and/or CSF positive; LGI1 abs at any titer in CSF and/or serum; CASPR2 abs &#x0003e;1:128 in serum and/or CSF positive.<sup><a href="#R20" rid="R20" class=" bibr popnode">20</a></sup> Only IgG abs were considered relevant.</p><p class="p p-last">Data on any immunotherapy were recorded. First-line immunotherapy was defined as treatment with corticosteroids, plasma exchange/immunoabsorption, and IVIG; second-line therapy included rituximab in the rituximab cohort and all other immunotherapies except reapplied corticosteroids, IVIG, and plasma exchange in both cohorts. The occurrence of relapses during follow-up was based on the overall clinical impression of the treating physician. Functional status was assessed using the modified Rankin Scale (mRS) at the peak of disease and then throughout disease course. Side effects of rituximab treatment were queried from all participating centers.</p></div><div id="s1-1-3" class="sec"><p></p><h4 id="s1-1-3title" class="inline">Primary Research Question </h4><p class="p p-first-last">Do rituximab-treated patients with NMDAR-AE, LGI1-AE, CASPR2-AE, and GAD65 disease have a better outcome than non&#x02013;rituximab-treated patients?</p></div><div id="s1-1-4" class="sec"><p></p><h4 id="s1-1-4title" class="inline">Classification of Evidence </h4><p class="p p-first-last">This study provides Class IV evidence that rituximab is an effective treatment for some types of AE.</p></div><div id="s1-1-5" class="sec sec-last"><p></p><h4 id="s1-1-5title" class="inline">Statistics </h4><p class="p p-first-last">Statistical tests were performed using Prism Software (GraphPad). Normality testing was performed using the D'Agostino-Pearson omnibus test. Continuous variables with &#x0003e;2 subgroups were compared using the Kruskal-Wallis test followed by the Dunn multiple comparisons test and with 2 subgroups using the Mann-Whitney test. Ordinal variables were compared using the &#x003c7;<sup>2</sup> test or the Fisher exact test. The Benjamini-Hochberg procedure was performed to control for multiple testing. Multivariate analysis was performed by ordinal logistic fit using JMP software (Version 16, JMP, A Business Unit of SAS, Cary, NC).</p></div></div><div id="s1-2" class="sec sec-last"><h3 id="s1-2title">Data Availability</h3><p class="p p-first-last">No deidentified patient data will be shared. No study-related documents will be shared. Reasonable requests from any qualified investigator for anonymized data will be considered by the corresponding author.</p></div></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">Results</h2><div id="s2-1" class="sec sec-first"><h3 id="s2-1title">Patient Characteristics</h3><p class="p p-first">We identified 358 patients with NMDAR-AE, GAD65 disease, LGI1-AE, or CASPR2-AE. One hundred sixty-three patients (46%) were treated with rituximab. Based on the inclusion criteria, 14 patients in the rituximab cohort and 32 patients in the control cohort were excluded from further analysis (<a href="/pmc/articles/PMC8488759/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>, eFigure 1, <a href="http://links.lww.com/NXI/A595" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">links.lww.com/NXI/A595</a>). Our final study cohort comprised 149 patients in the rituximab cohort (NMDAR-AE: n = 81, GAD65 disease: n = 31, LGI1-AE: n = 26, and CASPR2-AE: n = 11) and 163 patients in the control cohort (NMDAR-AE: n = 61, GAD65 disease: n = 53, LGI1-AE: n = 35, and CASPR2-AE: n = 14) (<a href="/pmc/articles/PMC8488759/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>). Overall, rituximab was administered most frequently in NMDAR-AE (57%), followed by CASPR2-AE (44%), LG1-1-AE (43%), and GAD65 disease (37%). Clinical characteristics as well as CSF and MRI parameters, as expected, varied considerably between the ab subgroups (<a href="/pmc/articles/PMC8488759/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). Differences between the rituximab cohort and the control cohort indicating severity bias were observed for patients with NMDAR-AE and GAD65 disease: patients with NMDAR-AE treated with rituximab had a significantly higher mRS score at peak of disease (rituximab cohort: median: 4.0; control cohort: median: 3.0) and a significantly higher frequency of decreased consciousness (<a href="/pmc/articles/PMC8488759/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). In patients with GAD65 disease, the mRS score at the peak of disease was also higher in the rituximab cohort (median: 3.0) compared with the control cohort (median: 2.0) (<a href="/pmc/articles/PMC8488759/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC8488759/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139757123517488"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761f1.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761f1.jpg" src="/pmc/articles/PMC8488759/bin/NEURIMMINFL2021038761f1.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139757123517488"><a target="object" rel="noopener" href="/pmc/articles/PMC8488759/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC8488759/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Study Population Profile</strong><p>Patient numbers in the different study subpopulations are depicted. *Patients excluded because of insufficient data on rituximab dosing (n = 2), concomitant diagnosis of MS (n = 2), retraction of consent for the GENERATE registry (n = 1), or not fulfilling the ab criteria for inclusion (n = 9). **Patients excluded because of insufficient data on immunosuppressive treatment (n = 1) or not fulfilling the ab criteria for inclusion (n = 31). CA, cerebellar ataxia; CASPR2 = contactin-associated protein-like-2; Enc. = encephalitis; GAD65 = glutamic acid decarboxylase 65; GENERATE = GErman Network for Research on AuToimmune Encephalitis; LGI1 = leucine-rich glioma-inactivated-1; NMDAR = NMDA receptor; SPS = stiff-person syndrome.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p>Characterization of the Patient Cohort</p></div><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139757123515152"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8488759_NEURIMMINFL2021038761T1.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761T1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC8488759/bin/NEURIMMINFL2021038761T1.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139757123515152"><a target="object" rel="noopener" href="/pmc/articles/PMC8488759/table/T1/?report=objectonly">Open in a separate window</a></div></div></div><div id="s2-2" class="sec"><h3 id="s2-2title">First-Line and Second-Line Treatments</h3><p class="p p-first">All patients with rituximab treatment received prior first-line immunotherapy. In the control cohort, 4 patients (7%) with NMDAR-AE, 5 patients (9%) with GAD65 disease, and 1 patient (7%) with CASPR2-AE had no prior first-line immunotherapy (<a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). Time to initiation of first-line therapy was shortest in patients with NMDAR-AE, and the therapy was started significantly earlier in patients with NMDAR-AE treated with rituximab (median: 16 days) compared with patients with NMDAR-AE not receiving rituximab (median: 33 days) (<a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). In all subgroups, the majority of patients received a combination of different first-line treatments with steroids and plasma exchange being the most frequent combination in the overall cohort (n = 103; 33%) (<a href="/pmc/articles/PMC8488759/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2, A&#x02013;H</span></a>). As expected, because of severity bias, patients in the rituximab cohort were treated significantly more often with combinations of first-line therapy (<a href="/pmc/articles/PMC8488759/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2, A&#x02013;H</span></a>). Physicians reported some improvement following first-line therapy in the majority of patients independent of the subgroup. Of interest, the frequency of this observation was similar between patients later receiving rituximab and patients who were treated differently (<a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p>Immunotherapy and Follow-up of Patients</p></div><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139757123506368"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8488759_NEURIMMINFL2021038761T2.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761T2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC8488759/bin/NEURIMMINFL2021038761T2.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139757123506368"><a target="object" rel="noopener" href="/pmc/articles/PMC8488759/table/T2/?report=objectonly">Open in a separate window</a></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC8488759/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139757123498368"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8488759_NEURIMMINFL2021038761f2.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761f2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC8488759/bin/NEURIMMINFL2021038761f2.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139757123498368"><a target="object" rel="noopener" href="/pmc/articles/PMC8488759/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC8488759/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Venn/Euler Diagrams Showing Applied Mono- and Combination First-Line and Second-Line Immunotherapies</strong><p>The numbers of patients treated with the respective prior first-line immunotherapies (A&#x02013;H) and second-line immunotherapies (I&#x02013;P) in the rituximab cohort (A&#x02013;D) and in the control cohort (E&#x02013;H) are depicted for the different ab subgroups (A, E, I, and M: NMDAR-AE; B, F, J, and N: GAD65 disease; C, G, K, and O: LGI1-AE; and D, H, L, and P: CASPR2-AE). Other second-line therapies included bortezomib (n = 6 in patients with NMDAR-AE treated with rituximab), daratumumab (n = 1 in patients with NMDAR-AE treated with rituximab), tacrolimus (n = 1 in patients with GAD65 disease treated with rituximab and n = 1 in patients with GAD65 disease not treated with rituximab), and basiliximab (n = 1 in patients with GAD65 disease treated with rituximab). Areas of Venn diagrams are proportional to the case numbers relative to the respective subgroup. (A&#x02013;H) Proportions of combination first-line therapy relative to none/monotherapy were compared using the Fisher exact test. ***<em>p</em> &#x0003c; 0.001, **<em>p</em> &#x0003c; 0.01, and *<em>p</em> &#x0003c; 0.05. (I&#x02013;P) Proportions of treatment with cyclophosphamide or other therapies relative to steroid-sparing therapies and no treatment were compared using the Fisher exact test. ***<em>p</em> &#x0003c; 0.001, **<em>p</em> &#x0003c; 0.01, and *<em>p</em> &#x0003c; 0.05. AZA = azathioprine; CASPR2 = contactin-associated protein-like-2; cyc = cyclophosphamide; GAD65 = glutamic acid decarboxylase 65; IVIG = IV immunoglobulin; MMF = mycophenolate mofetil; MTX = methotrexate; NMDAR = NMDA receptor; LGI1 = leucine-rich glioma-inactivated-1; PLEX = plasma exchange.</p></div></div></div><p class="p p-last">Forty patients (25%) in the control cohort and 38 patients (26%) in the rituximab cohort received a second-line immunotherapy other than rituximab. The frequency of application of second-line immunotherapies other than rituximab did not differ between the rituximab cohort and the control cohort (<a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). These second-line immunotherapies included cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, bortezomib, daratumumab, tacrolimus, and basiliximab (<a href="/pmc/articles/PMC8488759/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2, I&#x02013;P</span></a>) and were applied before, parallel to, or after rituximab therapy. In patients with NMDAR-AE and GAD65 disease, more aggressive second-line therapies such as cyclophosphamide, bortezomib, or daratumumab were applied more frequently in the rituximab cohort compared with the control cohort (<a href="/pmc/articles/PMC8488759/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2, I&#x02013;P</span></a>). Other than this and the above-mentioned severity bias, we did not observe significant selection bias between patients treated with and without rituximab.</p></div><div id="s2-3" class="sec"><h3 id="s2-3title">Description of Rituximab Treatments</h3><p class="p p-first">A wide spectrum of rituximab treatment regimens was observed in our rituximab cohort. In detail, patients with GAD65 disease and CASPR2-AE received rituximab significantly later (GAD65: median 1,209 days, CASPR2: 632 days) than patients with NMDAR-AE (median: 54 days) and LGI1-AE (median: 155 days) (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3A</span></a>; <a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). Time from initiation of first-line treatment to rituximab treatment was shortest in NMDAR-AE (median: 30 days) and longest in GAD65 disease (median: 141 days) (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3B</span></a>; <a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). Sixteen (20%) patients with NMDAR-AE received rituximab very early within 2 weeks after first-line immunotherapy. The median number of infusions and total rituximab dose did not differ significantly among the subgroups (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3C, D</span></a>; <a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The duration of rituximab treatment, defined as the time from first to last infusion, was shortest in NMDAR-AE (median: 24 days) and longest in GAD65 disease (median: 454 days) (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3E</span></a> and <a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The percentage of patients who received only induction therapy defined as time between first to last rituximab treatment of less than 6 months was highest in patients with NMDAR-AE (54%) and lowest in patients with GAD65 abs (27%); patients with LGI1- and CASPR2-AE were in between (35% and 46%, respectively) (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3F</span></a>; <a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). Side effects after rituximab treatment were rare (n = 5, 3.4%); however, they were not systematically registered in this study. In detail, we observed n = 2 infusion-related reactions (n = 1: urticaria with, however, simultaneous IVIG application; n = 1: tremor, tachycardia, and fear); n = 1 lymphopenia leading to a reduction of the rituximab dose; n = 1 frequent infections; and n = 1 unknown side effect.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139757119047648"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8488759_NEURIMMINFL2021038761f3.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761f3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC8488759/bin/NEURIMMINFL2021038761f3.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139757119047648"><a target="object" rel="noopener" href="/pmc/articles/PMC8488759/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC8488759/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Rituximab Regimens Used in Patients With AE and the Outcome According to Subtypes of AE</strong><p>(A&#x02013;F) In different subgroups (NMDAR-AE, GAD65 disease, LGI1-AE, and CASPR2-AE), the duration in days from disease onset to initiation of rituximab treatment (A), the duration in days from initiation of first-line therapy to initiation of rituximab treatment (B), the number of rituximab infusions (C), the total cumulative rituximab dose (D), the duration in days from the first to the last rituximab infusion (E), and the number of patients receiving induction therapy (rituximab treatment &#x0003c;6 months) or induction + maintenance therapy (rituximab treatment &#x02265;6 months) (F) are depicted. Bars indicate the median. Normality testing was performed using the D'Agostino-Pearson omnibus test. Continuous variables were compared using the Kruskal-Wallis test followed by the Dunn multiple comparisons test, and ordinal variables were compared using the Fisher exact test. ****<em>p</em>&#x0003c;0.0001 ***<em>p</em> &#x0003c; 0.001, **<em>p</em> &#x0003c; 0.01, and *<em>p</em> &#x0003c; 0.05. (G) mRS scores in the different ab subgroups were compared in the rituximab cohort and in the control cohort. The distribution of mRS scores is depicted at 4 time points: I, maximal mRS at symptom onset; II, mRS at initiation of rituximab treatment (from &#x02212;2 months to +4 months from rituximab onset); III, mRS 4&#x02013;12 months after initiation of rituximab treatment; IV, mRS at last follow-up with at least &#x0003e;12 months after rituximab treatment. The line represents the change in mRS scores dividing favorable mRS scores (0&#x02013;2) and nonfavorable mRS scores (&#x02265;3). The ordinal &#x003c7;<sup>2</sup> test was applied to compare the distribution of mRS scores. ****<em>p</em>&#x0003c;0.0001 ***<em>p</em> &#x0003c; 0.001, **<em>p</em> &#x0003c; 0.01, and *<em>p</em> &#x0003c; 0.05. CASPR2, contactin-associated protein-like-2; GAD65 = glutamic acid decarboxylase 65; mRS = modified Rankin Scale; NMDAR = NMDA receptor; LGI1 = leucine-rich glioma-inactivated-1.</p></div></div></div></div><div id="s2-4" class="sec sec-last"><h3 id="s2-4title">Follow-up and Treatment Response</h3><p class="p p-first">Follow-up data were available for 282 patients (90%) with a median follow-up duration of 41 months with no significant differences between rituximab-treated patients and controls regarding follow-up data availability and duration (<a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The distribution of mRS scores at the peak of disease and at last follow-up improved significantly in patients with NMDAR-AE and in patients with LGI1-AE both in the rituximab cohort and in the control cohort. In patients with CASPR2-AE, a significant improvement was observed only in the rituximab cohort, but not in the control cohort. No significant improvement was observed in patients with GAD65 disease (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3G</span></a>). In addition, in patients with GAD65 disease, no significant improvement was observed when mRS scores were analyzed in the different disease subentities (encephalitis/overlap syndrome, CA, and SPS) (eFigure 2A, <a href="http://links.lww.com/NXI/A596" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">links.lww.com/NXI/A596</a>).</p><p>Although patients with NMDAR-AE treated with rituximab were affected more severely at baseline (<a href="/pmc/articles/PMC8488759/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>), at final follow-up, 94% of rituximab-treated patients compared with 88% of nontreated patients had reached independent living (mRS score &#x02264;2, <em>p</em> = 0.33). Patients with LGI1-AE reached independent living in 83% of cases treated with rituximab and in 78% of cases without rituximab treatment (<em>p</em> = 0.74). In CASPR2-AE, independent living was observed in 80% of cases treated with rituximab vs 57% of cases who did not receive B-cell depletion (<em>p</em> = 0.60). In contrast, patients with GAD65 disease treated with rituximab, who were more severely affected at baseline, continued to have a lower rate of independent living compared with the non&#x02013;rituximab-treated control cohort at last follow-up (52% vs 75%, <em>p</em> = 0.07).</p><p>When we analyzed the mRS scores in the rituximab cohort throughout follow-up in more detail, we found patients with NMDAR-AE to improve significantly already before rituximab initiation (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3, G.a I-II</span></a>), presumably because of first-line treatments. After initiation of rituximab treatment, patients continued to improve significantly (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3G.a II-III</span></a>). No significant difference in the mRS score was observed in patients with NMDAR-AE exhibiting a tumor compared with those without a tumor both regarding mRS score at worst status and mRS score at last follow-up (eFigure 2B, <a href="http://links.lww.com/NXI/A596" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">links.lww.com/NXI/A596</a>). In LGI1 patients, a significant improvement was also already observed before rituximab treatment was initiated (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3G.c I-II</span></a>). After initiation of rituximab treatment, the mRS scores continued to drop; however, this improvement did not reach statistical significance (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3G.c II-IV</span></a>). In patients with CASPR2-AE, mRS scores decreased after initiation of rituximab treatment (<a href="/pmc/articles/PMC8488759/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3G.d II-IV</span></a>) without reaching significance presumably because of small patient numbers.</p><p>Nineteen relapses (14%) were reported during follow-up in the rituximab cohort (NMDAR-AE: n = 13, 19%; LGI1-AE: n = 5, 20%; and CASPR2-AE: n = 1, 11%). Of note, only 6 relapses (5%) in the rituximab cohort occurred after rituximab treatment was started (NDMAR-AE: n = 3, 4%; LGI1-AE: n = 3; 12%) (<a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The other 13 relapses occurred before rituximab initiation. In the control cohort, 19 relapses (13%) occurred (NMDAR-AE: n = 7, 13%; LGI1-AE: n = 10, 31%; CASPR2-AE: n = 2, 14%), which was more frequent than those observed in the rituximab group after initiation of rituximab (<em>p</em> = 0.02) (<a href="/pmc/articles/PMC8488759/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>).</p><p class="p">Finally, we performed a multivariate analysis for the rituximab cohort to identify factors associated with the extent of improvement as measured by the change in the mRS score from baseline to last follow-up. Most significantly, the AE subtype (NMDAR-AE) was associated with mRS score improvement, whereas rituximab dosage and duration were not significantly associated with an improved mRS score (<a href="/pmc/articles/PMC8488759/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). MRS score improvement was also observed for early initiation of rituximab treatment (&#x02264;60 days after initiation of first-line treatment), and a trend was observed for early initiation of first-line treatment (&#x02264;30 days after symptom onset).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p>Multivariate Analysis of the Outcome</p></div><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139757119022960"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761T3.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761T3.jpg" src="/pmc/articles/PMC8488759/bin/NEURIMMINFL2021038761T3.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139757119022960"><a target="object" rel="noopener" href="/pmc/articles/PMC8488759/table/T3/?report=objectonly">Open in a separate window</a></div></div></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">Discussion</h2><p class="p p-first">This study describes real-world data on rituximab usage in a large German cohort of patients with the most common AE subtypes. We confirm the following: (1) Rituximab is the most frequent second-line immunotherapy that is used in nearly half of all patients with AE in Germany. (2) Rituximab usage differs within AE subtypes with patients with NMDAR-AE most frequently and patients with GAD65 disease least frequently receiving rituximab. Treatment was in all cases initiated following prior first-line immunotherapy. Patients with NMDAR-AE and GAD65 disease were more likely to be treated with rituximab if they presented with more severe disease (decreased levels of consciousness and higher mRS). (3) Patients with NMDAR-AE were treated earlier and more often (54%) received a short-term rituximab treatment (&#x0003c;6 months) without repeated maintenance reinfusion than other AE subgroups. (4) The long-term outcome in patients with NMDAR-, LGI1-, and CASPR2-AE in the overall cohort was favorable with 91%, 80%, and 63% of the patients being able to function independently at last follow-up, respectively. (5) Although comparison of patients with and without rituximab treatment is prone to severity bias, we found some hints of a better outcome and fewer relapses in the former group: patients with NMDAR-AE treated with rituximab more often reached independent living at last follow-up although being affected more severely at baseline; patients with CASPR2-AE improved significantly better under rituximab treatment; patients with NMDAR-E and LGI1-AE experienced fewer relapses if treated with rituximab. (6) No significant improvement during follow-up of patients with GAD65 disease was observed both in the rituximab cohort and in the control cohort. However, although we did not observe a group effect in GAD65 disease, some individuals showed a remarkable response associated with B cell&#x02013;depleting treatment.</p><p>In NMDAR-AE, treatment with rituximab is widely accepted. It has been used empirically since the first description of NMDAR-AE, and a large prospective case series<sup><a href="#R4" rid="R4" class=" bibr popnode">4</a></sup> and a systematic review<sup><a href="#R21" rid="R21" class=" bibr popnode">21</a></sup> could add further evidence that early second-line immunotherapy in patients not responding sufficiently to first-line immunotherapy was associated with better outcomes and fewer relapses. Recently, a meta-analysis of 14 retrospective and prospective case series summarizing 277 patients with AE (88.8% NMDAR-AE) concluded that rituximab is an effective second-line agent with an acceptable toxicity profile.<sup><a href="#R19" rid="R19" class=" bibr popnode">19</a></sup> Our data confirm and extend these observations. We found patients with NMDAR-AE treated with rituximab to have a favorable outcome. As patients treated with induction or maintenance therapy did not significantly differ in the outcome, our data support the notion that in many patients with NMDAR-AE, short-term rituximab treatment might be sufficient to control the disease. In a recent position paper by the Autoimmune Encephalitis Alliance Clinicians Network,<sup><a href="#R22" rid="R22" class=" bibr popnode">22</a></sup> this is reflected by the recommendation to consider long-term rituximab treatment mainly in relapsing disease.</p><p>Compared with NMDAR-AE, considerably less information on long-term immunosuppression and especially rituximab is available in other AE subtypes. For LGI1-AE, early initiation of any immune therapy was associated with better outcomes in studies with 29<sup><a href="#R7" rid="R7" class=" bibr popnode">7</a></sup> and 13 patients,<sup><a href="#R23" rid="R23" class=" bibr popnode">23</a></sup> respectively. Only few patients were treated with rituximab in retrospective case series<sup><a href="#R19" rid="R19" class=" bibr popnode">19</a>,<a href="#R24" rid="R24" class=" bibr popnode">24</a>,<a href="#R25" rid="R25" class=" bibr popnode">25</a></sup> and a small open-label trial.<sup><a href="#R26" rid="R26" class=" bibr popnode">26</a></sup> In our cohort, we observed a surprisingly favorable outcome in patients with LGI1-AE, with 80% reaching independent living (mRS score &#x02264;2) (83% in the rituximab cohort and 78% in the control cohort). A systematic review<sup><a href="#R21" rid="R21" class=" bibr popnode">21</a></sup> showed full recovery or an mRS score of 0 in 27.8% of patients, with 8% of patients treated with rituximab and 18% of patients receiving second-line treatment. In light of these findings, we believe that rituximab treatment can be considered early in patients with LGI1-AE as 1 possible immunosuppressive treatment, although the duration of therapy is unclear.</p><p>Relapses occurred in 16% of patients with NMDAR-AE and 26% with LGI1-AE in our overall cohort. Previously, relapses were reported in 11.2% (85/758) of patients with NMDAR-AE and 18.8% (16/85) with LGI1-AE.<sup><a href="#R21" rid="R21" class=" bibr popnode">21</a></sup> However, we did observe a reduced rate of relapses in patients with NMDAR-AE and LGI1-AE treated with rituximab compared with patients without (independent of other second-line immunotherapies) suggesting better efficacy of rituximab in preventing relapses compared with other regimens. Nevertheless, this should be interpreted with caution because absolute patient numbers are small and controlled studies missing.</p><p>For the treatment of CASPR2-AE, even less evidence exists. In our series, 44% of patients with CASPR2-AE (n = 11) were treated with rituximab albeit considerably later than patients with NMDAR-AE. We could show significant improvement in patients with CASPR2-AE treated with rituximab, which was not observed in the control group. Although patient numbers were small, our results suggest an effect of rituximab treatment in CASPR2-AE but also indicate the need for larger numbers.</p><p>Immunotherapeutic strategies for GAD65-AE remain highly controversial.<sup><a href="#R27" rid="R27" class=" bibr popnode">27</a></sup> Most patients are considered to require immunotherapy, and early immunotherapy has been found to be associated with a better outcome.<sup><a href="#R10" rid="R10" class=" bibr popnode">10</a>,<a href="#R28" rid="R28" class=" bibr popnode">28</a></sup> However, the different neurologic manifestations of SPS, CA, and LE appear to respond differently to treatments.<sup><a href="#R27" rid="R27" class=" bibr popnode">27</a></sup> Treatment of SPS with IVIG has been examined in a small crossover placebo-controlled trial in 16 patients with SPS<sup><a href="#R11" rid="R11" class=" bibr popnode">11</a></sup> and showed efficacy in approximately 80% of patients. The use of plasma exchange and corticosteroids was linked to ambiguous clinical responses,<sup><a href="#R29" rid="R29" class=" bibr popnode">29</a>,<a href="#R30" rid="R30" class=" bibr popnode">30</a></sup> and immunosuppressive agents such as azathioprine, methotrexate, cyclophosphamide, and mycophenolate mofetil are currently used in clinical practice, however, with insufficient evidence from larger clinical trials.<sup><a href="#R30" rid="R30" class=" bibr popnode">30</a>,<a href="#R31" rid="R31" class=" bibr popnode">31</a></sup> Rituximab was examined in a randomized, placebo-controlled trial in 24 patients with GAD65-SPS yet surprisingly did not show significant effects, possibly because of the long disease duration at the time of treatment initiation (8.0 years).<sup><a href="#R15" rid="R15" class=" bibr popnode">15</a></sup> The long-term outcome in SPS in general was poor, with 40% of patients not responding to immunotherapy.<sup><a href="#R32" rid="R32" class=" bibr popnode">32</a></sup> Although small case series show a benefit from immunotherapy including rituximab in GAD65-CA in 41%&#x02013;48% of cases,<sup><a href="#R33" rid="R33" class=" bibr popnode">33</a>,<a href="#R34" rid="R34" class=" bibr popnode">34</a></sup> the long-term outcome is poor in approximately 65% of patients.<sup><a href="#R10" rid="R10" class=" bibr popnode">10</a></sup> Similarly, most patients with GAD65-LE continue to have seizures with or without immunotherapy.<sup><a href="#R35" rid="R35" class=" bibr popnode">35</a>,<a href="#R36" rid="R36" class=" bibr popnode">36</a></sup> Our data are in line with these observations. Rituximab treatment was initiated very late after onset of symptoms in our patients, and we did not find a significant association with a better outcome in these patients. Yet, the functional level was better than expected with 67% of patients being able to live independently (mRS score &#x02264;2) (52% in the rituximab group and 75% in the control group). In summary, our data support the notion that long-standing GAD65 disease does not respond to rituximab therapy. However, patients in early disease stages might be more likely to respond to rituximab treatment; however, response is difficult to predict, and a lack of response should trigger benefit-risk reevaluation of rituximab therapy.</p><p>We analyzed data acquired by the GENERATE network, a multicenter registry for AE in Germany. Of note, all participating centers had experience in treatment of AE, and thus, our study is not necessarily representative for nonexpert centers or centers outside Germany. Further limitations of our study are the observational character going along with a severity bias when patients with and without rituximab treatment are compared and the difficulty to differentiate rituximab treatment effects from spontaneous improvements or improvements due to concomitant treatments, the incomplete follow-up data with potential selection bias, and the lack of clinical criteria defining response to first-line therapies. Nevertheless, because randomized trials are difficult to conduct in rare diseases such as AE, real-world data from registries add important information on treatment profiles and sequences and may lead to standardized treatment protocols. In addition, single-center bias is unlikely due to the multicenter approach. Analysis of auto-ab levels, B-cell counts, and biomarkers like serum neurofilament light chain concentration throughout treatment course could add to future studies investigating the response to rituximab treatment in AE. In addition, safety data should be captured systematically.</p><p class="p p-last">Our results support the efficacy of early rituximab treatment in NMDAR-, LGI1-, and CASPR2-AE and suggest that short-term therapy could be a treatment option. They also suggest that patients with long-standing GAD65 disease are less likely to benefit from B-cell depletion than the other AE subgroups. Nevertheless, future controlled, randomized, and prospective studies in addition to national and supranational registries with collaborative research efforts are in dire need in the field of AE. As an example of such collaborative research, the multicentric, double-blinded, and placebo-controlled phase II study GENERATE-BOOST is currently investigating the response to bortezomib in patients with severe AE.</p></div><div id="ack-a.w.a" class="tsec sec"><h2 class="head no_bottom_margin" id="ack-a.w.atitle">Acknowledgment</h2><div class="sec"><p>The authors thank the patients and relatives contributing by donating their pseudonymized data and biomaterials to the GENERATE network.</p></div></div><div id="glossary-a.w.e" class="tsec sec"><h2 class="head no_bottom_margin" id="glossary-a.w.etitle">Glossary</h2><div class="bk-sec"><div><table class="default-table glossary"><tbody><tr><td id="G1">abs</td><td>antibodies</td></tr><tr><td id="G2">AE</td><td>autoimmune encephalitis</td></tr><tr><td id="G3">CA</td><td>cerebellar ataxia</td></tr><tr><td id="G4">CASPR2</td><td>contactin-associated protein-like-2</td></tr><tr><td id="G5">CBA</td><td>cell-based assay</td></tr><tr><td id="G6">GAD65</td><td>glutamic acid decarboxylase 65</td></tr><tr><td id="G7">GENERATE</td><td>GErman Network for Research on AuToimmune Encephalitis</td></tr><tr><td id="G8">IHC</td><td>immunohistochemistry</td></tr><tr><td id="G9">IVIG</td><td>IV immunoglobulin</td></tr><tr><td id="G10">LE</td><td>limbic/autoimmune encephalitis</td></tr><tr><td id="G11">LGI1</td><td>leucine-rich glioma-inactivated-1</td></tr><tr><td id="G12">mRS</td><td>Modified Rankin Scale</td></tr><tr><td id="G13">NMDAR</td><td>NMDA receptor</td></tr><tr><td id="G14">RIA</td><td>radioimmunoassay</td></tr><tr><td id="G15">SPS</td><td>stiff-person syndrome</td></tr></tbody></table></div></div></div><div id="A1" class="tsec sec"><h2 class="head no_bottom_margin" id="A1title">Appendix 1. Authors</h2><!--/article/back/app-group/app/--><p>
<!--table ft1--><!--table-wrap mode="anchored" t5--></p><div class="table-wrap anchored whole_rhythm" id="TU1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139757124405840"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761TU1.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761TU1.jpg" src="/pmc/articles/PMC8488759/bin/NEURIMMINFL2021038761TU1.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139757124405840"><a target="object" rel="noopener" href="/pmc/articles/PMC8488759/table/TU1/?report=objectonly">Open in a separate window</a></div></div><p>
</p></div><div id="A2" class="tsec sec"><h2 class="head no_bottom_margin" id="A2title">Appendix 2. Coinvestigators</h2><!--/article/back/app-group/app/--><p>
<!--table ft1--><!--table-wrap mode="anchored" t5--></p><div class="table-wrap anchored whole_rhythm" id="TU2"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139757124402576"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8488759_NEURIMMINFL2021038761TU2.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NEURIMMINFL2021038761TU2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC8488759/bin/NEURIMMINFL2021038761TU2.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139757124402576"><a target="object" rel="noopener" href="/pmc/articles/PMC8488759/table/TU2/?report=objectonly">Open in a separate window</a></div></div><p>
</p></div><div id="sec-a.w.b" class="tsec bk-sec"><h2 class="head no_bottom_margin" id="sec-a.w.btitle">Study Funding</h2><!--/article/back/sec/--><p class="p p-first-last">This work was supported by the Else Kr&#x000f6;ner Fresenius Stiftung (2011_A154), the Gemeinn&#x000fc;tzige Hertie Stiftung, the Bundesministerium f&#x000fc;r Bildung und Forschung (CONNECT-GENERATE, 01GM1908), and the Munich Cluster for Systems Neurology (SyNergy).</p></div><div id="sec-a.w.c" class="tsec bk-sec"><h2 class="head no_bottom_margin" id="sec-a.w.ctitle">Disclosure</h2><!--/article/back/sec/--><p class="p p-first-last">The authors report no disclosures relevant to the manuscript. Go to <a href="https://nn.neurology.org/content/8/6/e088/tab-article-info" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Neurology.org/NN</a> for full disclosures.</p></div><div id="ref-list-a.w.f" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.w.ftitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="mixed-citation">Leypoldt F, Armangue T, Dalmau J. <span class="ref-title">Autoimmune encephalopathies</span>. <span class="ref-journal">Ann N Y Acad Sci.</span>
2015;<span class="ref-vol">1338</span>(<span class="ref-iss">1</span>):94-114. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4363225/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25315420" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+N+Y+Acad+Sci.&amp;title=Autoimmune+encephalopathies&amp;volume=1338&amp;issue=1&amp;publication_year=2015&amp;pages=94-114&amp;pmid=25315420&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="mixed-citation">Graus F, Titulaer MJ, Balu R, et al.. 
<span class="ref-title">A clinical approach to diagnosis of autoimmune encephalitis</span>. <span class="ref-journal">Lancet Neurol.</span>
2016;<span class="ref-vol">15</span>(<span class="ref-iss">4</span>):391-404. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5066574/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26906964" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Neurol.&amp;title=A+clinical+approach+to+diagnosis+of+autoimmune+encephalitis&amp;volume=15&amp;issue=4&amp;publication_year=2016&amp;pages=391-404&amp;pmid=26906964&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="mixed-citation">Dalmau J, Gleichman AJ, Hughes EG, et al.. 
<span class="ref-title">Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</span>. <span class="ref-journal">Lancet Neurol.</span>
2008;<span class="ref-vol">7</span>(<span class="ref-iss">12</span>):1091-1098. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2607118/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18851928" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Neurol.&amp;title=Anti-NMDA-receptor+encephalitis:+case+series+and+analysis+of+the+effects+of+antibodies&amp;volume=7&amp;issue=12&amp;publication_year=2008&amp;pages=1091-1098&amp;pmid=18851928&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="mixed-citation">Titulaer MJ, McCracken L, Gabilondo I, et al.. 
<span class="ref-title">Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study</span>. <span class="ref-journal">Lancet Neurol.</span>
2013;<span class="ref-vol">12</span>(<span class="ref-iss">2</span>):157-165. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3563251/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23290630" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Neurol.&amp;title=Treatment+and+prognostic+factors+for+long-term+outcome+in+patients+with+anti-NMDA+receptor+encephalitis:+an+observational+cohort+study&amp;volume=12&amp;issue=2&amp;publication_year=2013&amp;pages=157-165&amp;pmid=23290630&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="mixed-citation">Irani SR, Alexander S, Waters P, et al.. 
<span class="ref-title">Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia</span>. <span class="ref-journal">Brain.</span>
2010;<span class="ref-vol">133</span>(<span class="ref-iss">9</span>):2734-2748. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2929337/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20663977" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Brain.&amp;title=Antibodies+to+Kv1+potassium+channel-complex+proteins+leucine-rich,+glioma+inactivated+1+protein+and+contactin-associated+protein-2+in+limbic+encephalitis,+Morvan's+syndrome+and+acquired+neuromyotonia&amp;volume=133&amp;issue=9&amp;publication_year=2010&amp;pages=2734-2748&amp;pmid=20663977&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="mixed-citation">Lai M, Huijbers MG, Lancaster E, et al.. 
<span class="ref-title">Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series</span>. <span class="ref-journal">Lancet Neurol.</span>
2010;<span class="ref-vol">9</span>(<span class="ref-iss">8</span>):776-785. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3086669/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20580615" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Neurol.&amp;title=Investigation+of+LGI1+as+the+antigen+in+limbic+encephalitis+previously+attributed+to+potassium+channels:+a+case+series&amp;volume=9&amp;issue=8&amp;publication_year=2010&amp;pages=776-785&amp;pmid=20580615&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="mixed-citation">Irani SR, Michell AW, Lang B, et al.. 
<span class="ref-title">Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis</span>. <span class="ref-journal">Ann Neurol.</span>
2011;<span class="ref-vol">69</span>(<span class="ref-iss">5</span>):892-900. [<a href="https://pubmed.ncbi.nlm.nih.gov/21416487" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Neurol.&amp;title=Faciobrachial+dystonic+seizures+precede+Lgi1+antibody+limbic+encephalitis&amp;volume=69&amp;issue=5&amp;publication_year=2011&amp;pages=892-900&amp;pmid=21416487&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="mixed-citation">Lancaster E, Martinez-Hernandez E, Dalmau J. <span class="ref-title">Encephalitis and antibodies to synaptic and neuronal cell surface proteins</span>. <span class="ref-journal">Neurology.</span>
2011;<span class="ref-vol">77</span>(<span class="ref-iss">2</span>):179-189. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3140073/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21747075" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology.&amp;title=Encephalitis+and+antibodies+to+synaptic+and+neuronal+cell+surface+proteins&amp;volume=77&amp;issue=2&amp;publication_year=2011&amp;pages=179-189&amp;pmid=21747075&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="mixed-citation">Irani SR, Pettingill P, Kleopa KA, et al.. 
<span class="ref-title">Morvan syndrome: clinical and serological observations in 29 cases</span>. <span class="ref-journal">Ann Neurol.</span>
2012;<span class="ref-vol">72</span>(<span class="ref-iss">2</span>):241-255. [<a href="https://pubmed.ncbi.nlm.nih.gov/22473710" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Neurol.&amp;title=Morvan+syndrome:+clinical+and+serological+observations+in+29+cases&amp;volume=72&amp;issue=2&amp;publication_year=2012&amp;pages=241-255&amp;pmid=22473710&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="mixed-citation">Arino H, Gresa-Arribas N, Blanco Y, et al.. 
<span class="ref-title">Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy</span>. <span class="ref-journal">JAMA Neurol.</span>
2014;<span class="ref-vol">71</span>(<span class="ref-iss">8</span>):1009-1016. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4841264/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24934144" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Neurol.&amp;title=Cerebellar+ataxia+and+glutamic+acid+decarboxylase+antibodies:+immunologic+profile+and+long-term+effect+of+immunotherapy&amp;volume=71&amp;issue=8&amp;publication_year=2014&amp;pages=1009-1016&amp;pmid=24934144&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="mixed-citation">Dalakas MC, Li M, Fujii M, Jacobowitz DM. <span class="ref-title">Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies</span>. <span class="ref-journal">Neurology.</span>
2001;<span class="ref-vol">57</span>(<span class="ref-iss">5</span>):780-784. [<a href="https://pubmed.ncbi.nlm.nih.gov/11552003" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology.&amp;title=Stiff+person+syndrome:+quantification,+specificity,+and+intrathecal+synthesis+of+GAD65+antibodies&amp;volume=57&amp;issue=5&amp;publication_year=2001&amp;pages=780-784&amp;pmid=11552003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="mixed-citation">Giometto B, Miotto D, Faresin F, Argentiero V, Scaravilli T, Tavolato B. <span class="ref-title">Anti-gabaergic neuron autoantibodies in a patient with stiff-man syndrome and ataxia</span>. <span class="ref-journal">J Neurol Sci.</span>
1996;<span class="ref-vol">143</span>(<span class="ref-iss">1&#x02212;2</span>):57-59. [<a href="https://pubmed.ncbi.nlm.nih.gov/8981298" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol+Sci.&amp;title=Anti-gabaergic+neuron+autoantibodies+in+a+patient+with+stiff-man+syndrome+and+ataxia&amp;volume=143&amp;issue=1&#x02212;2&amp;publication_year=1996&amp;pages=57-59&amp;pmid=8981298&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="mixed-citation">Gresa-Arribas N, Arino H, Martinez-Hernandez E, et al.. 
<span class="ref-title">Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity</span>. <span class="ref-journal">PLoS One.</span>
2015;<span class="ref-vol">10</span>(<span class="ref-iss">3</span>):e0121364. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4361655/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25774787" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One.&amp;title=Antibodies+to+inhibitory+synaptic+proteins+in+neurological+syndromes+associated+with+glutamic+acid+decarboxylase+autoimmunity&amp;volume=10&amp;issue=3&amp;publication_year=2015&amp;pages=e0121364&amp;pmid=25774787&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="mixed-citation">Dubey D, Britton J, McKeon A, et al.. 
<span class="ref-title">Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy</span>. <span class="ref-journal">Ann Neurol.</span>
2020;<span class="ref-vol">87</span>(<span class="ref-iss">2</span>):313-323. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7003900/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31782181" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Neurol.&amp;title=Randomized+placebo-controlled+trial+of+intravenous+immunoglobulin+in+autoimmune+LGI1/CASPR2+epilepsy&amp;volume=87&amp;issue=2&amp;publication_year=2020&amp;pages=313-323&amp;pmid=31782181&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="mixed-citation">Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. <span class="ref-title">A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome</span>. <span class="ref-journal">Ann Neurol.</span>
2017;<span class="ref-vol">82</span>(<span class="ref-iss">2</span>):271-277. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5755707/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28749549" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Neurol.&amp;title=A+double-blind,+placebo-controlled+study+of+rituximab+in+patients+with+stiff+person+syndrome&amp;volume=82&amp;issue=2&amp;publication_year=2017&amp;pages=271-277&amp;pmid=28749549&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="mixed-citation">Hauser SL, Waubant E, Arnold DL, et al.. 
<span class="ref-title">B-cell depletion with rituximab in relapsing-remitting multiple sclerosis</span>. <span class="ref-journal">N Engl J Med.</span>
2008;<span class="ref-vol">358</span>(<span class="ref-iss">7</span>):676-688. [<a href="https://pubmed.ncbi.nlm.nih.gov/18272891" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med.&amp;title=B-cell+depletion+with+rituximab+in+relapsing-remitting+multiple+sclerosis&amp;volume=358&amp;issue=7&amp;publication_year=2008&amp;pages=676-688&amp;pmid=18272891&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="mixed-citation">Trebst C, Jarius S, Berthele A, et al.. 
<span class="ref-title">Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)</span>. <span class="ref-journal">J Neurol.</span>
2014;<span class="ref-vol">261</span>(<span class="ref-iss">1</span>):1-16. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3895189/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24272588" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol.&amp;title=Update+on+the+diagnosis+and+treatment+of+neuromyelitis+optica:+recommendations+of+the+Neuromyelitis+Optica+Study+Group+(NEMOS)&amp;volume=261&amp;issue=1&amp;publication_year=2014&amp;pages=1-16&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="mixed-citation">Lee WJ, Lee ST, Byun JI, et al.. 
<span class="ref-title">Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort</span>. <span class="ref-journal">Neurology.</span>
2016;<span class="ref-vol">86</span>(<span class="ref-iss">18</span>):1683-1691. [<a href="https://pubmed.ncbi.nlm.nih.gov/27037228" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology.&amp;title=Rituximab+treatment+for+autoimmune+limbic+encephalitis+in+an+institutional+cohort&amp;volume=86&amp;issue=18&amp;publication_year=2016&amp;pages=1683-1691&amp;pmid=27037228&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="mixed-citation">Nepal G, Shing YK, Yadav JK, et al.. 
<span class="ref-title">Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis</span>. <span class="ref-journal">Acta Neurol Scand.</span>
2020;<span class="ref-vol">142</span>(<span class="ref-iss">5</span>):449-459. [<a href="https://pubmed.ncbi.nlm.nih.gov/32484900" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Scand.&amp;title=Efficacy+and+safety+of+rituximab+in+autoimmune+encephalitis:+a+meta-analysis&amp;volume=142&amp;issue=5&amp;publication_year=2020&amp;pages=449-459&amp;pmid=32484900&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="mixed-citation">Bien CG, Bien CI, Dogan Onugoren M, et al.. 
<span class="ref-title">Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome</span>. <span class="ref-journal">J Neurol.</span>
2020;<span class="ref-vol">267</span>(<span class="ref-iss">7</span>):2101-2114. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8213550/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32246252" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol.&amp;title=Routine+diagnostics+for+neural+antibodies,+clinical+correlates,+treatment+and+functional+outcome&amp;volume=267&amp;issue=7&amp;publication_year=2020&amp;pages=2101-2114&amp;pmid=32246252&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="mixed-citation">Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. <span class="ref-title">Immune therapy in autoimmune encephalitis: a systematic review</span>. <span class="ref-journal">Expert Rev Neurother.</span>
2015;<span class="ref-vol">15</span>(<span class="ref-iss">12</span>):1391-1419. [<a href="https://pubmed.ncbi.nlm.nih.gov/26559389" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Neurother.&amp;title=Immune+therapy+in+autoimmune+encephalitis:+a+systematic+review&amp;volume=15&amp;issue=12&amp;publication_year=2015&amp;pages=1391-1419&amp;pmid=26559389&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="mixed-citation">Abboud H, Probasco J, Irani SR, et al.. 
<span class="ref-title">Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management</span>. <span class="ref-journal">J Neurol Neurosurg Psychiatry.</span>
2015;<span class="ref-vol">15</span>(<span class="ref-iss">12</span>):1391-1419. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8292591/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33649021" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol+Neurosurg+Psychiatry.&amp;title=Autoimmune+encephalitis:+proposed+recommendations+for+symptomatic+and+long-term+management&amp;volume=15&amp;issue=12&amp;publication_year=2015&amp;pages=1391-1419&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="mixed-citation">Shin YW, Lee ST, Shin JW, et al.. 
<span class="ref-title">VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy</span>. <span class="ref-journal">J Neuroimmunol.</span>
2013;<span class="ref-vol">265</span>(<span class="ref-iss">1-2</span>):75-81. [<a href="https://pubmed.ncbi.nlm.nih.gov/24176648" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol.&amp;title=VGKC-complex/LGI1-antibody+encephalitis:+clinical+manifestations+and+response+to+immunotherapy&amp;volume=265&amp;issue=1-2&amp;publication_year=2013&amp;pages=75-81&amp;pmid=24176648&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="mixed-citation">Arino H, Armangue T, Petit-Pedrol M, et al.. 
<span class="ref-title">Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome</span>. <span class="ref-journal">Neurology.</span>
2016;<span class="ref-vol">87</span>(<span class="ref-iss">8</span>):759-765. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4999321/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27466467" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology.&amp;title=Anti-LGI1-associated+cognitive+impairment:+Presentation+and+long-term+outcome&amp;volume=87&amp;issue=8&amp;publication_year=2016&amp;pages=759-765&amp;pmid=27466467&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="mixed-citation">van Sonderen A, Thijs RD, Coenders EC, et al.. 
<span class="ref-title">Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up</span>. <span class="ref-journal">Neurology.</span>
2016;<span class="ref-vol">87</span>(<span class="ref-iss">14</span>):1449-1456. [<a href="https://pubmed.ncbi.nlm.nih.gov/27590293" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology.&amp;title=Anti-LGI1+encephalitis:+clinical+syndrome+and+long-term+follow-up&amp;volume=87&amp;issue=14&amp;publication_year=2016&amp;pages=1449-1456&amp;pmid=27590293&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="mixed-citation">Irani SR, Gelfand JM, Bettcher BM, Singhal NS, Geschwind MD. <span class="ref-title">Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy</span>. <span class="ref-journal">JAMA Neurol.</span>
2014;<span class="ref-vol">71</span>(<span class="ref-iss">7</span>):896-900. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4477824/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24842754" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Neurol.&amp;title=Effect+of+rituximab+in+patients+with+leucine-rich,+glioma-inactivated+1+antibody-associated+encephalopathy&amp;volume=71&amp;issue=7&amp;publication_year=2014&amp;pages=896-900&amp;pmid=24842754&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="mixed-citation">Graus F, Saiz A, Dalmau J. <span class="ref-title">GAD antibodies in neurological disorders - insights and challenges</span>. <span class="ref-journal">Nat Rev Neurol.</span>
2020;<span class="ref-vol">16</span>(<span class="ref-iss">7</span>):353-365. [<a href="https://pubmed.ncbi.nlm.nih.gov/32457440" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Neurol.&amp;title=GAD+antibodies+in+neurological+disorders+-+insights+and+challenges&amp;volume=16&amp;issue=7&amp;publication_year=2020&amp;pages=353-365&amp;pmid=32457440&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="mixed-citation">Di Giacomo R, Deleo F, Pastori C, et al.. 
<span class="ref-title">Predictive value of high titer of GAD65 antibodies in a case of limbic encephalitis</span>. <span class="ref-journal">J Neuroimmunol.</span>
2019;<span class="ref-vol">337</span>:577063. [<a href="https://pubmed.ncbi.nlm.nih.gov/31525619" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol.&amp;title=Predictive+value+of+high+titer+of+GAD65+antibodies+in+a+case+of+limbic+encephalitis&amp;volume=337&amp;publication_year=2019&amp;pages=577063&amp;pmid=31525619&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="mixed-citation">Vasconcelos OM, Dalakas MC. <span class="ref-title">Stiff-person syndrome</span>. <span class="ref-journal">Curr Treat Options Neurol.</span>
2003;<span class="ref-vol">5</span>(<span class="ref-iss">1</span>):79-90. [<a href="https://pubmed.ncbi.nlm.nih.gov/12521565" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Treat+Options+Neurol.&amp;title=Stiff-person+syndrome&amp;volume=5&amp;issue=1&amp;publication_year=2003&amp;pages=79-90&amp;pmid=12521565&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="mixed-citation">Tsiortou P, Alexopoulos H, Dalakas MC. <span class="ref-title">GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions</span>. <span class="ref-journal">Ther Adv Neurol Disord.</span>
2021;<span class="ref-vol">14</span>:17562864211003486. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8013924/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33854562" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ther+Adv+Neurol+Disord.&amp;title=GAD+antibody-spectrum+disorders:+progress+in+clinical+phenotypes,+immunopathogenesis+and+therapeutic+interventions&amp;volume=14&amp;publication_year=2021&amp;pages=17562864211003486&amp;pmid=33854562&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="mixed-citation">Hao W, Davis C, Hirsch IB, et al.. 
<span class="ref-title">Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study</span>. <span class="ref-journal">J Neurol.</span>
1999;<span class="ref-vol">246</span>(<span class="ref-iss">8</span>):731-735. [<a href="https://pubmed.ncbi.nlm.nih.gov/10460456" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol.&amp;title=Plasmapheresis+and+immunosuppression+in+stiff-man+syndrome+with+type+1+diabetes:+a+2-year+study&amp;volume=246&amp;issue=8&amp;publication_year=1999&amp;pages=731-735&amp;pmid=10460456&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="mixed-citation">McKeon A, Robinson MT, McEvoy KM, et al.. 
<span class="ref-title">Stiff-man syndrome and variants: clinical course, treatments, and outcomes</span>. <span class="ref-journal">Arch Neurol.</span>
2012;<span class="ref-vol">69</span>(<span class="ref-iss">2</span>):230-238. [<a href="https://pubmed.ncbi.nlm.nih.gov/22332190" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Neurol.&amp;title=Stiff-man+syndrome+and+variants:+clinical+course,+treatments,+and+outcomes&amp;volume=69&amp;issue=2&amp;publication_year=2012&amp;pages=230-238&amp;pmid=22332190&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="mixed-citation">Mitoma H, Hadjivassiliou M, Honnorat J. <span class="ref-title">Guidelines for treatment of immune-mediated cerebellar ataxias</span>. <span class="ref-journal">Cerebellum Ataxias.</span>
2015;<span class="ref-vol">2</span>:14. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4641375/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26561527" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cerebellum+Ataxias.&amp;title=Guidelines+for+treatment+of+immune-mediated+cerebellar+ataxias&amp;volume=2&amp;publication_year=2015&amp;pages=14&amp;pmid=26561527&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="mixed-citation">Jones AL, Flanagan EP, Pittock SJ, et al.. 
<span class="ref-title">Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults</span>. <span class="ref-journal">JAMA Neurol.</span>
2015;<span class="ref-vol">72</span>(<span class="ref-iss">11</span>):1304-1312. [<a href="https://pubmed.ncbi.nlm.nih.gov/26414229" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Neurol.&amp;title=Responses+to+and+outcomes+of+treatment+of+autoimmune+cerebellar+ataxia+in+adults&amp;volume=72&amp;issue=11&amp;publication_year=2015&amp;pages=1304-1312&amp;pmid=26414229&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="mixed-citation">Daif A, Lukas RV, Issa NP, et al.. 
<span class="ref-title">Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy</span>. <span class="ref-journal">Epilepsy Behav.</span>
2018;<span class="ref-vol">80</span>:331-336. [<a href="https://pubmed.ncbi.nlm.nih.gov/29433947" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsy+Behav.&amp;title=Antiglutamic+acid+decarboxylase+65+(GAD65)+antibody-associated+epilepsy&amp;volume=80&amp;publication_year=2018&amp;pages=331-336&amp;pmid=29433947&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="mixed-citation">Malter MP, Frisch C, Zeitler H, et al.. 
<span class="ref-title">Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies</span>. <span class="ref-journal">Seizure.</span>
2015;<span class="ref-vol">30</span>:57-63. [<a href="https://pubmed.ncbi.nlm.nih.gov/26216686" ref="reftype=pubmed&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Seizure.&amp;title=Treatment+of+immune-mediated+temporal+lobe+epilepsy+with+GAD+antibodies&amp;volume=30&amp;publication_year=2015&amp;pages=57-63&amp;pmid=26216686&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=8488759&amp;issue-id=387389&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Neurology&#x00ae; Neuroimmunology &#x0026; Neuroinflammation</span> are provided here courtesy of <strong>American Academy of Neurology</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC8488759/pdf/NEURIMMINFL2021038761.pdf" class="int-view">PDF (917K)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/8488759/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/8488759/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="8488759" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8488759%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="FG7nwHrnuFnq6XA6fN2jrscw4I00S2jOjoYvrLYEOh97P1UFz2An5rMtDJP7W2fP">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8488759%2F&amp;text=Rituximab%20Treatment%20and%20Long-term%20Outcome%20of%20Patients%20With%20Autoimmune%20Encephalitis%3A%20Real-world%20Evidence%20From%20the%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8488759%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488759/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC8488759/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/34599001/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC8488759/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/34599001/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC8488759/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/8488759/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC8488759/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
